Duvelisib (IPI-145) is a selective, orally bioavailable PI3K inhibitor with IC50 values of 2.5 nM for p110δ and 27.4 nM for p110γ. It modulates immune responses and shows efficacy in models of arthritis, asthma, lupus, and certain cancers, with potential applications in immunotherapy. Reagent grade, for research use only.
Usually ships within 24 hours.